Celularity (CELU) Receivables - Net (2020 - 2025)

Celularity (CELU) posted quarterly Receivables - Net of $116.0 for Q4 2025, down 100.0% quarter-over-quarter from $6.7 million in Q3 2025.

Celularity (CELU) Receivables - Net (2020 - 2025) Analysis & Trends

Celularity (CELU) has reported Receivables - Net for 6 consecutive years, with $116.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Receivables - Net changed N/A year-over-year to $116.0; the TTM figure through Dec 2025 stood at $116.0 (changed N/A YoY), while the FY2025 annual figure was $4.7 million, down 65.68% from the prior year.
Receivables - Net slipped to $116.0 in Q4 2025 per CELU's latest filing, from $6.7 million in the prior quarter.
Across five years, Receivables - Net topped out at $15.0 million in Q1 2025 and bottomed at $116.0 in Q4 2025.
Historically, Receivables - Net has averaged $6.5 million across 5 years, with a median of $4.5 million in 2022.
Annual changes were most pronounced in 2023 — Receivables - Net retreated 28.5% — and 2024, when it jumped 379.09%.
Celularity's Receivables - Net stood at $2.7 million in 2021, then surged by 62.19% to $4.5 million in 2022, then soared by 125.65% to $10.0 million in 2023, then slipped by 12.7% to $8.8 million in 2024, then slumped by 100.0% to $116.0 in 2025.
Business Quant data shows CELU's Receivables - Net at $116.0 in Q4 2025, $6.7 million in Q3 2025, and $11.2 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Celularity	20.99 Mn	14.82 Mn	-3.27 Mn

Download Data